# Central Post-Stroke Pain Syndrome

Central post-stroke pain is a diagnosis of lesion-concordant central neuropathic pain after stroke. Confirm the sensory phenotype and lesion, exclude common peripheral and musculoskeletal post-stroke pain generators, then individualize medication trials and consider neuromodulation for refractory disability.

**Clinical question:** How should physicians diagnose and manage central post-stroke pain while excluding competing post-stroke pain syndromes?

Updated: 2026-08-21T01:49:12.651380+00:00

## What matters in practice
- Diagnose central post-stroke pain clinically only after linking pain and sensory abnormalities to a stroke lesion on CT or MRI and excluding other post-stroke pain generators. [19][20]
- Mixed pain is common after stroke; spasticity, shoulder pathology, headache, and shoulder-hand syndrome can coexist with central post-stroke pain and require separate treatment pathways. [9][20]
- Amitriptyline, lamotrigine, pregabalin, and gabapentin have evidence of benefit in central neuropathic pain, but treatment response is incomplete and tolerability frequently determines selection. [5][17][24]
- For persistent, function-limiting pain despite medication trials, refer to a pain or neurostimulation center to consider noninvasive neuromodulation; high-frequency repetitive transcranial magnetic stimulation has shown moderate pain reduction in randomized-trial meta-analysis. [6][7]

## Identify central pain without missing a new structural complication

CPSP is a lesion-related central neuropathic pain syndrome, not a diagnosis assigned to all pain after stroke.

Treat abrupt new focal deficits, acute severe headache, altered consciousness, fever with meningismus, or rapidly escalating pain as a possible new cerebrovascular, infectious, or other structural event rather than established CPSP. Obtain urgent neuroimaging when the clinical change raises concern for new stroke, hemorrhage, or another intracranial lesion; prior stroke does not make subsequent symptoms attributable to chronic central pain. CT or MRI is also required to document the original lesion's type, location, and size when establishing CPSP. [19][22]

CPSP results from stroke-related damage to the central somatosensory nervous system and may arise from lesions beyond the thalamus; avoid restricting the diagnosis to the historical term thalamic pain. Symptoms commonly begin 3 to 6 months after stroke, although onset is variable. The clinical consequence is a delay-prone diagnosis in patients whose pain appears after the acute rehabilitation period. [8][20]

Ask the patient to map the painful territory relative to the stroke deficits, then examine pinprick, temperature, light touch, vibration, proprioception, and evoked pain in the painful and contralateral homologous areas. A lesion-concordant distribution with sensory loss, dysesthesia, allodynia, or hyperalgesia supports central neuropathic pain; a normal or mechanically localized examination should redirect the workup toward a nociceptive, peripheral nerve, or regional pain syndrome. [19][20]
- Document baseline pain intensity, sleep disruption, mood symptoms, and functional targets before initiating a medication trial; chronic post-stroke pain is associated with sleep disturbance, depression, and functional impairment. [20]
- Review the timing of pain relative to stroke, its distribution, sensory triggers, temperature sensitivity, movement dependence, and whether passive range of motion reproduces pain; these features separate central from musculoskeletal and spasticity-related components. [9][19][20]

*Post-stroke pain patterns that redirect the diagnostic and treatment pathway. [9][18][19][20]*

| Pain pattern | Discriminating findings | Next action |
| --- | --- | --- |
| Central post-stroke pain | Pain in a stroke-concordant body region with sensory abnormalities, including paresthesia, hyperalgesia, or allodynia; correlate with CT or MRI lesion. [19][20] | Exclude competing pain generators; begin a neuropathic-pain medication trial and reassess function and adverse effects. [5][17][24] |
| Spasticity or contracture-related pain | Pain linked to increased tone, abnormal posture, muscle spasm, or limited passive range of motion rather than a sensory-evoked pain phenotype. [9][20] | Address the movement disorder and rehabilitation impairment; do not expect central-pain pharmacotherapy alone to correct a contracture. [9][20] |
| Hemiplegic shoulder pain or structural shoulder disorder | Pain localized to the shoulder and provoked by movement or examination of the shoulder complex. [9][20] | Perform focused shoulder examination and direct treatment to the musculoskeletal diagnosis. [9][20] |
| Shoulder-hand syndrome | Affected upper-limb edema, finger and shoulder pain, erythema, increased skin temperature, restricted joint motion, and skin or muscle changes; often occurs 1 to 3 months after cerebrovascular disease. [18] | Evaluate as a regional post-stroke pain syndrome rather than assuming CPSP; prioritize limb-specific rehabilitation and syndrome-directed management. [18][20] |
| Post-stroke headache | Head-pain phenotype rather than lesion-concordant limb or hemibody sensory pain. [9][20] | Classify the headache and evaluate for secondary causes when the onset or neurologic examination is concerning. [9][22] |

## Use lesion concordance and sensory examination to establish CPSP

No single biomarker confirms CPSP; diagnosis rests on convergent clinical and imaging evidence.

Confirm the cerebrovascular lesion on CT or MRI, then determine whether the lesion plausibly involves central somatosensory pathways relevant to the painful territory. Imaging supports causal attribution and excludes alternative intracranial pathology, but imaging alone does not diagnose CPSP because pain after stroke often has mixed causes. [19][9]

Use a structured sensory examination rather than symptom labels alone. Compare painful with nonpainful regions for hypoesthesia, hyperalgesia, dynamic mechanical allodynia, and cold-evoked pain. Quantitative sensory testing and somatosensory evoked potentials can characterize sensory abnormalities, but the core diagnostic approach remains history, clinical sensory examination, and lesion imaging. [19]

Actively search for coexisting pain mechanisms at each reassessment. A patient may have CPSP plus spasticity, shoulder subluxation, contracture, or shoulder-hand syndrome; failure of a neuropathic agent may therefore indicate an untreated second generator rather than absence of CPSP. [9][18][20]
- Map pain and sensory deficits in the medical record so that later change can be distinguished from a new neurologic syndrome. [19][22]
- Use medication response as supportive clinical information, not as a diagnostic test; incomplete benefit is common with available pharmacologic options. [7][17]
- Escalate to neurology or pain medicine when the lesion-pain relationship is uncertain, pain is disabling despite first medication trials, or mixed central and peripheral mechanisms cannot be separated clinically. [20][22]

### Practical diagnostic threshold

Classify pain as probable CPSP when all three elements are present: a documented prior stroke lesion, pain distributed plausibly relative to that lesion, and a compatible sensory phenotype on examination after reasonable exclusion of musculoskeletal, spasticity-related, headache, and regional limb syndromes. This synthesis reflects the recommended combination of history, sensory examination, imaging, and exclusion of competing diagnoses. [19][20]

*Core elements for clinical attribution of central post-stroke pain. [19][20]*

| Element | What to document | Interpretation |
| --- | --- | --- |
| Stroke confirmation | CT or MRI showing stroke lesion, including lesion type, location, and size. [19] | Establishes the CNS injury required for CPSP attribution. [8][19] |
| Pain-topography relationship | Body-region distribution and relationship to prior neurologic deficits. [19] | A lesion-concordant pattern strengthens attribution; a focal joint or peripheral nerve distribution should trigger an alternative workup. [19][20] |
| Somatosensory phenotype | Pinprick, temperature, touch, vibration, proprioception, allodynia, and hyperalgesia testing. [19][20] | Sensory abnormalities support central neuropathic pain and guide symptom-targeted monitoring. [19] |
| Alternative generators | Tone, range of motion, shoulder examination, hand edema and skin temperature, and headache phenotype. [9][18][20] | A positive alternative diagnosis may coexist with CPSP but requires separate treatment. [9][20] |

## Select and titrate a medication trial around comorbidity and tolerability

Set functional targets and use one interpretable trial at a time whenever feasible.

Amitriptyline has randomized-trial evidence in CPSP, with pain-intensity reduction reported during the fourth and final treatment week in a controlled trial. Consider it when sleep disturbance coexists, but weigh anticholinergic burden, sedation, orthostasis, and cardiac risk against expected benefit, particularly in older stroke survivors. [5][12][24]

Lamotrigine reduced CPSP and cold allodynia at 200 mg/day in a controlled study. Its role is most useful when an oral alternative to a tricyclic is needed; titrate cautiously and stop for a clinically concerning rash because dose escalation is constrained by cutaneous toxicity risk. [24]

Pregabalin and gabapentin are established options for central neuropathic pain, although large-scale CPSP trials remain limited. For pregabalin, a cited regimen is 75 mg once or twice daily initially, with increase to 300 mg/day within 1 week based on efficacy and tolerability; selected patients may require a lower 25 mg starting dose and slower escalation after stroke. Adjust pregabalin for renal impairment. [17][24]

For patients with creatinine clearance of at least 60 mL/min, pregabalin dosing cited for central neuropathic pain is 75 to 150 mg twice daily or 50 to 100 mg three times daily; doses may be increased to 600 mg/day after a further 2 to 4 weeks when benefit and tolerability justify escalation. Reassess dizziness, somnolence, edema, gait safety, and functional effect during titration, especially when the patient already has post-stroke fall risk. [24]

Avoid treating CPSP as an opioid-responsive nociceptive syndrome. Long-term opioid treatment has been associated with worse outcomes than short-term treatment in a population-based neuropathic-pain cohort, and chronic opioid prescribing guidance emphasizes confirming the diagnosis and addressing disease-specific and nonpharmacologic interventions. Reserve any opioid decision for exceptional circumstances with explicit reassessment of benefit, harms, and alternatives. [7][22]
- Choose amitriptyline when an evening sedating agent and mood or sleep benefit are desired, but avoid or limit it when anticholinergic or orthostatic effects create unacceptable risk. [12][24]
- Choose pregabalin when renal-adjusted dosing and gradual titration are feasible; start lower and titrate more slowly in medication-sensitive post-stroke patients. [24]
- Consider lamotrigine when cold allodynia is prominent or when tricyclic therapy is poorly tolerated; use the 200 mg/day efficacy signal as the target rather than rapid escalation. [24]
- At each follow-up, continue only if pain reduction produces a patient-defined gain in sleep, mobility, therapy participation, or daily function; otherwise taper or switch rather than accumulating ineffective agents. [20][22]

*Medication options with cited CPSP or central-neuropathic-pain evidence. [5][12][17][24]*

| Agent | Cited dosing or efficacy signal | Selection and monitoring considerations |
| --- | --- | --- |
| Amitriptyline | Controlled CPSP trial reported significant pain-intensity decrease in week 4. [12] | Consider sleep and mood burden; monitor sedation, anticholinergic effects, orthostasis, and cardiac tolerability. [5][12][24] |
| Lamotrigine | Reduced CPSP and cold allodynia at 200 mg/day. [24] | Titrate cautiously; monitor for rash and discontinue for concerning cutaneous reactions. [24] |
| Pregabalin | Start 75 mg once or twice daily; may increase to 300 mg/day within 1 week. With creatinine clearance at least 60 mL/min, cited dosing is 75-150 mg twice daily or 50-100 mg three times daily; up to 600 mg/day after another 2-4 weeks. [24] | Adjust for renal impairment; consider 25 mg starting dose and slower titration in medication-sensitive post-stroke patients. [24] |
| Gabapentin | Reported effective for central neuropathic pain, with evidence extrapolated partly from other central pain states. [24] | Use as an alternative gabapentinoid when pregabalin is not tolerated or accessible; monitor sedation and gait effects. [24] |

## Escalate refractory disability to multidisciplinary and neuromodulation care

Persistent pain requires reassessment of diagnosis, concurrent pain mechanisms, and treatment goals before procedural escalation.

Before labeling CPSP refractory, repeat the lesion-concordance and sensory assessment, review adherence and dose-limiting adverse effects, and identify untreated spasticity, shoulder pathology, contracture, or shoulder-hand syndrome. This step is essential because several post-stroke pain syndromes frequently coexist and a central analgesic will not resolve a mechanical or regional limb process. [9][18][20]

Integrate physical therapy and psychologically informed pain care when pain limits mobility, limb use, sleep, or rehabilitation participation. Stretching and exercise may help functional impairment, although empirical evidence is limited; use therapy to preserve movement and address the noncentral components of post-stroke pain rather than presenting it as a replacement for lesion-directed neuropathic pain treatment. [20]

Consider referral for noninvasive neuromodulation when medication trials are inadequate or poorly tolerated and pain remains function-limiting. A 2024 systematic review and meta-analysis of randomized CPSP trials reported moderate pain-intensity reduction with high-frequency repetitive transcranial magnetic stimulation. This is a reasonable specialty-level option, with counseling that central-pain pharmacotherapies and stimulation strategies often provide partial rather than complete relief. [6][7]

Invasive neurostimulation, including spinal cord stimulation, remains a last-resort approach in chronic neuropathic pain and is controversial in CPSP. Reserve evaluation for highly selected patients in experienced centers after diagnostic confirmation, rehabilitation optimization, and noninvasive options; patient selection should account for uncertain long-term benefit and procedural burden. [7]
- Refer to pain medicine or a neuromodulation program for persistent disabling CPSP after medication intolerance or inadequate benefit from reasonable trials. [6][7][20]
- Maintain stroke rehabilitation involvement when pain causes guarding, reduced range of motion, or declining limb use; examine for shoulder-hand syndrome if edema, erythema, warmth, or distal stiffness appears. [18][20]
- Screen for sleep and mood effects at follow-up because these consequences amplify disability and are common in untreated CPSP. [20]

*Escalation pathway for persistent central post-stroke pain. [6][7][18][20]*

| Clinical problem | Required reassessment | Next step |
| --- | --- | --- |
| No meaningful benefit from initial medication | Verify lesion-pain concordance, sensory phenotype, adherence, adverse effects, and coexisting mechanical or regional pain syndromes. [9][19][20] | Switch to or trial an alternative evidence-supported neuropathic agent rather than assuming all pain is central. [5][17][24] |
| Pain blocks rehabilitation or limb use | Assess tone, passive range of motion, shoulder pathology, and shoulder-hand syndrome features. [9][18][20] | Coordinate targeted rehabilitation and treatment of the identified noncentral pain generator. [18][20] |
| Disabling pain despite medication trials | Confirm diagnosis and review functional goals, mood, sleep, and medication tolerability. [20][22] | Refer for consideration of high-frequency repetitive transcranial magnetic stimulation. [6] |
| Persistent severe refractory pain after noninvasive strategies | Reconfirm mixed mechanisms and discuss realistic benefit versus procedure burden. [7][20] | Consider evaluation at an experienced center for invasive neuromodulation only as a last-resort strategy. [7] |

## Monitor function, adverse effects, and evolution of competing pain syndromes

Pain score alone is insufficient; continue treatment only when it improves an agreed clinical outcome.

At medication initiation, define one or two measurable goals such as improved sleep continuity, increased therapy participation, more independent transfers, or tolerance of limb use. At each titration visit, document pain intensity, allodynia or cold sensitivity, daytime sedation, dizziness, edema, falls, mood, and sleep. This prevents escalation of a drug that lowers a numeric pain score without functional gain. [20][24]

Re-examine the affected limb when the phenotype changes. New edema, erythema, warmth, stiffness, or finger pain favors shoulder-hand syndrome; new pain with restricted passive range of motion or increased tone favors musculoskeletal or spasticity-related pathology. Redirect management to the new or coexisting diagnosis rather than simply increasing a central analgesic. [9][18][20]

Use shared decisions when benefit is partial. Current pharmacologic options for CPSP have limited benefit overall, and the clinical target is meaningful reduction of disability and distress rather than complete analgesia. Patients with persistent functional impairment should remain connected to stroke rehabilitation and pain-focused follow-up while neuromodulation options are considered. [7][20]
- For pregabalin, confirm renal function for dose adjustment and reassess sedation, dizziness, edema, and gait safety during each dose increase. [24]
- For amitriptyline, reassess orthostasis, anticholinergic effects, daytime sedation, and cardiac tolerability before further escalation. [12][24]
- For lamotrigine, specifically ask about rash during titration and discontinue promptly for a concerning eruption. [24]

*Follow-up targets that determine whether to continue, switch, or escalate therapy. [18][20][24]*

| Domain | Assess at follow-up | Action if unfavorable |
| --- | --- | --- |
| Function | Sleep, mobility, limb use, transfers, and rehabilitation participation. [20] | If no meaningful functional gain, reassess diagnosis and change strategy rather than continuing an ineffective regimen. [20][22] |
| Medication tolerability | Sedation, dizziness, edema, gait safety, orthostasis, anticholinergic effects, and rash according to agent. [12][24] | Reduce dose, switch agents, or stop the offending medication when harms outweigh functional benefit. [24] |
| Pain mechanism | Distribution, sensory findings, movement-provoked pain, tone, shoulder examination, and limb edema or warmth. [9][18][19][20] | Treat newly identified musculoskeletal, spasticity-related, or shoulder-hand syndrome components separately. [18][20] |
| Refractory burden | Persistent disability despite adequate trials and rehabilitation engagement. [6][7][20] | Refer for multidisciplinary pain assessment and consideration of noninvasive neuromodulation. [6][7] |

## References
1. Central post-stroke pain: clinical characteristics, ... — www.thelancet.com — https://www.thelancet.com/journals/laneur/article/PIIS1474442209701760/abstract
2. Pharmacotherapy and non-invasive neuromodulation for ... — www.thelancet.com — https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00068-7/fulltext
3. a systematic review and meta-analysis — www.thelancet.com — https://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422%2825%2900068-7.pdf
4. Central post-stroke pain: advances in clinical and ... — svn.bmj.com — https://svn.bmj.com/content/early/2024/09/27/svn-2024-003418
5. Management of Central Poststroke Pain | Stroke — www.ahajournals.org — https://www.ahajournals.org/doi/abs/10.1161/strokeaha.115.010259
6. Transcranial Magnetic Stimulation Applications in ... — www.nature.com — https://www.nature.com/nature-index/topics/l4/transcranial-magnetic-stimulation-applications-in-neuropathic-pain-management
7. Neuropathic pain | Nature Reviews Neurology — www.nature.com — https://www.nature.com/subjects/neuropathic-pain/nrneurol
8. Pathophysiology of Central Poststroke Pain | Stroke — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.025692
9. Prevalence, Trajectory, and Predictors of Poststroke Pain — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043355
10. Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review | Spinal Cord Series and Cases — www.nature.com — https://www.nature.com/articles/s41394-022-00529-3?fromPaywallRec=false
11. The diverse therapeutic actions of pregabalin: is a single ... — www.cell.com — https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(13)00062-X
12. Some Painful News about Central Post-Stroke Pain | AHA Blogs — www.ahajournals.org — https://www.ahajournals.org/do/10.1161/blog.20151005.200600/full
13. Comparison of the effects of acupuncture and drug treatment for central post-stroke pain: A systematic review and network meta-analysis of randomized trials - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0166432825005236
14. Comparison of the effects of acupuncture and drug ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0166432825005236
15. Treatment of central post-stroke pain with oral ketamine — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0304395900004887
16. Central Neuropathic Pain | Continuum — journals.lww.com — https://journals.lww.com/continuum/fulltext/2024/10000/central_neuropathic_pain.7.aspx
17. Pharmacotherapies for Central Post‐Stroke Pain: A ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2022/3511385
18. Acupuncture for shoulder-hand syndrome after stroke: An... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2022/11180/acupuncture_for_shoulder_hand_syndrome_after.67.aspx
19. Review Central post-stroke pain: clinical characteristics, ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1474442209701760
20. Central Post-Stroke Pain Syndrome - StatPearls - NCBI - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK604196
21. Central poststroke pain — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.51.5.1352
22. CDC Guideline for Prescribing Opioids for Chronic Pain — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm
23. Percutaneous adhesiolysis in the management of chronic low back pain in post lumbar surgery syndrome and spinal stenosis: a systematic review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK109134
24. Clinical use of pregabalin in the management of central neuropathic pain - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656330

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.